medigraphic.com
ISSN 1561-3054 (Electronic)

2021, Number 1

<< Back Next >>

Rev Cubana Med Trop 2021; 73 (1)

COVID-19: clinical presentation in patients admitted to ''Pedro Kourí'' Tropical Medicine Institute

Jiménez PNA, Fonseca GCM, Fonseca MCA, de la Paz BT, Martínez RA, Herrera MNL, Rodríguez BJA, Cárdenas GA, Baldoquín RW, Castro POE, Ortega GLM, Marrero MO, Pérez DAB, Sierra VB, Castaño AO, Miranda LY, González RD

Language: Spanish
References: 24
Page: 1-18
PDF size: 575.57 Kb.


ABSTRACT

Introduction: Upon appearance of the first COVID-19 cases in Cuba, early identification of patients at risk of developing severe forms of the disease became a necessity.
Objective: Describe the clinical behavior of COVID-19 in patients admitted to Pedro Kourí Tropical Medicine Institute and identify factors associated to severity.
Methods: A presentation was made of the first 73 COVID-19 cases admitted to Pedro Kourí Tropical Medicine Institute from 11 March to 5 May 2020. The patients were divided into two groups: severe and mild disease. A comparison was made of clinical, demographic, laboratory and imaging variables at admission, and their possible association to disease severity.
Results: Seven patients (9.6%) were critically ill; five died. Age > 60 years, more than one comorbidity, arterial hypertension and bronchial asthma were more common among critical patients. Fever for more than six days (p= 0.00), dyspnea (p= 0.00), presence of humid stertors (p= 0.00), respiratory rate > 24/min (p= 0.00) and lymphocytes < 0.8 x109/l (p= 0.00), ferritin > 500 µg/L (p =0.00), C-reactive protein 10 μg/l (p= 0.01) and LDH 500 U/l (p= 0.01) were related to disease severity. 18.2% of the chest radiographs showed alterations, with a predominance of bilateral foci of inflammatory condensation. The most common complications were respiratory distress, shock, bacterial sepsis and heart disorders.
Conclusions: Some clinical and laboratory characteristics identifiable at admission may be associated to disease severity, which makes them useful for risk stratification and the appropriate management of patients.


REFERENCES

  1. Feng Z, Li Q, Zhang Y, Wu Z, Dong X, Ma H, et al. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China, 2020. China CDC Weekly. 2020;2(8):113-22.

  2. World Health Organization. Coronavirus disease (COVID-19) pandemic. Geneva: WHO; 2019 [acceso: 15/05/2020]. Disponible en: Disponible en: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

  3. World Health Organization. Novel Coronavirus(2019-nCoV). Situation Report-53. 13 March 2020 [acceso: 15/05/2020]. Disponible en: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200313-sitrep-53-covid-19.pdf?sfvrsn=adb3f72_2

  4. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20. Disponible en: https://10.1056/NEJMoa2002032

  5. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chinese Medical Journal. 2020;133(9). Disponible en: https://10.1097/CM9.0000000000000744

  6. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. Journal of Infection. 2020. Disponible en: https://doi.org/10.1016/j.jinf.2020.03.041

  7. Molero García JM, Redondo Sánchez J, Arranz Izquierdo J. COVID-19. SARS-CoV-2. semFYC en Enfermedades Infecciosas [Internet]. 14 de abril de 2020. Disponible en: https://semFYC.es

  8. Fan Z, Chen L, Li J, Chen X, Yang J, Tian C, et al. Clinical faeture of COVID 19 related liver damage. Clin Gastroenterol Hepatol. 2020;S1542-3565(20):30482-1. Disponible en: https://10.1016/j.cgh.2020.04.002

  9. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System A Review. JAMA Cardiol. 2020. Disponible en: https://10.1001/jamacardio.2020.1286

  10. Infomed, Portal de la Red de Salud de Cuba. Protocolo cubano contraCOVID 19. Ministerio de Salud Pública. [acceso: 20/09 /2020]. Disponible en: https://instituciones.sld.cu/facultadfinlayalbarran/protocolo-cubavs-covid-4-4-2020

  11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62. Disponible en: https://doi.org/10.1016/

  12. Sama IE, Ravera A, Santema BT, van Goor H, Maaten JMt, Cleland JGF, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. European Heart Jou. 2020;41(1):1810-17. Disponible en:https://doi.org/10.1093/eurheartj/ehaa373

  13. Lala A, Johnson KW, Januzzi J, Russak AJ, Paranjpe I, Zhao S, et al. Prevalence and Impact of Myocardial Injury in Patients Hospitalized with COVID-19 Infection. 2020. Disponible en: https://doi.org/10.1101/2020.04.20.20072702

  14. Zhang JJ, Dong X, Cao YY, Dong YY, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARSCoV-2 in Wuhan, China. Allergy. 2020;00:1-12. Disponible en: https://10.1111/all.14238

  15. Lee N, Allen Chan K, Hui D, Ng E, Wu A, Chiu R, et al. Effects of early corticosteroid treatment on plasma SARS-associated coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304-9.

  16. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018;197(6):757-67. Disponible en: https:// 10.1164/rccm.201706-1172OC

  17. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 N Engl J Med 2020. Disponible en: https://doi.org/10.1056/NEJMoa2007621

  18. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020. Disponible en: https://doi.org/10.1056/NEJMoa2006923

  19. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9. Disponible en: https://doi.org/10.1172/JCI137244

  20. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. CellResearch. 2020;30(3):269-71. Disponible en: https://10.1038/s41422-020-0282-0

  21. Lim J, Jeon S, Shin H-Y, Kim M, Seong Y, Lee W, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantita. J Korean Med Sci . 2020 Feb 17;35(6):e79. doi: 10.3346/jkms.2020.35.e79

  22. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020;382(19):1787-99. Disponible en: https://10.1056/NEJMoa2001282

  23. El Sistema de Salud Pública frente a la COVID-19. Redacción MINSAP.12 de junio 2020. [acceso: 20/09 /2020]. Disponible en: https://salud.msp.gob.cu/el-sistema-de-salud-publica-frente-a-la-covid-19-93-dias-de-enfrentamiento/

  24. Díaz-Canel Bermúdez M, Nuñez Jover J. Gestión gubernamental y ciencia cubana en el enfrentamiento a la COVID-19. Anales de la Academia de Ciencias de Cuba. 2020;10(2).




2020     |     www.medigraphic.com